Having trouble accessing articles? Reset your cache.

CDX-1401: Preliminary Phase I/II data

Preliminary data from an ongoing, open-label, dose-escalation, U.S. Phase I/II trial in 20 patients, 35% of which had confirmed NY-ESO-1 expression,

Read the full 210 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE